---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-013249"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T03:41:20.997075+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ernexa shareholders approve reverse stock split, share increase to 150M, and written consent

## Summary
- Elected all five director nominees: James Bristol, Peter Cicala, Sanjeev Luther, Elena Ratner, William Wexler.
- Approved amendment to increase authorized common stock from 100M to 150M shares.
- Approved reverse stock split at Board's discretion within 1-for-10 to 1-for-15 ratio.
- Approved stockholder action by written consent, removing meeting-only requirement.
- Ratified Grant Thornton as auditor for 2025 and approved potential issuance >20% under March 31 securities purchase agreement.

## SEC filing metadata
- accession: 0001641172-25-013249
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000164117225013249/0001641172-25-013249-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000164117225013249/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-013249
- JSON: https://secwatch.observer/filing/0001641172-25-013249.json
- Plain text: https://secwatch.observer/filing/0001641172-25-013249.txt

## Key facts
- Governance Changes
  Ernexa Therapeutics Inc.: Allowed stockholder action by written consent in addition to meetings (effective 2025-06-02).
  - Change: charter amendment
  - Effective: 2025-06-02
  source text: Additionally, effectively June 2, 2025, the Company filed a certificate of amendment to its Amended COI with the Secretary of State of Delaware to allow for action required or permitted to be taken by stockholders of the Company to be effected by written consent of such stockholders in addition to duly called annual or special meetings of such stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000164117225013249/0001641172-25-013249-index.htm
- Governance Changes
  Ernexa Therapeutics Inc.: Increased authorized common stock from 100,000,000 to 150,000,000 (effective 2025-06-02).
  - Change: charter amendment
  - Effective: 2025-06-02
  source text: Effective June 2, 2025, Ernexa Therapeutics Inc. (the “Company”), filed a certificate of amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Amended COI”) with the Secretary of State of Delaware to increase the authorized shares of its common stock from 100,000,000 to 150,000,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000164117225013249/0001641172-25-013249-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.